In search of an Alzheimer's cure

October 29, 2018, University of Technology, Sydney
Credit: CC0 Public Domain

For decades, the field of Alzheimer's research has been dominated by a major hypothesis: that a build-up of beta amyloid (amyloid-β) in the brain causes Alzheimer's disease. However, despite years of research and billions of dollars spent on clinical trials, there is still no cure.

In a paper published in high-profile journal Acta Neuropathologica, researchers at the University of Technology Sydney outline evidence to question whether the emphasis on the is preventing the development of alternative – and potentially disruptive – theories in Alzheimer's research.

"Over the last 30 years, the majority of tested therapeutics for Alzheimer's disease have been directed toward removing amyloid-β. Although we see merit in this strategy, we suggest that disease initiation and progression is more complex than can be accounted for by amyloid-β alone," says Professor of Neuroscience and Director of the UTS Centre for Neuroscience and Regenerative Medicine, Bryce Vissel.

"Alzheimer's disease is a life-changing diagnosis for those living with the condition, their family and friends. We have written this article to encourage research leaders to think outside the box in their attempts to find ways to prevent, halt or reverse the course of the condition."

Prospective new research targets are yet to be fully understood. For example, existing research shows that vascular degeneration, neuroinflammation and synaptic neurodegeneration are all present during the progression of Alzheimer's disease, but their role remains unknown.

The researchers also argue that looking at brain pathology alone is insufficient to understand Alzheimer's, and that a more holistic approach to disease prediction and diagnosis is required – one that considers the unique features of each individual.

"Since amyloid-β and associated pathology is not at all unique to Alzheimer's disease, attempts to construct a mechanism for this condition based solely on it, not unexpectedly, continue to fail," says co-author Emeritus Professor Ian Clark of the Australian National University.

Further, the amyloid hypothesis has its own challenges: for example, many healthy individuals have amyloid-β without Alzheimer's, and there are also significant numbers of people diagnosed with the disease despite having no amyloid-β. What's more, there are at least nine known, modifiable for Alzheimer's that might not be linked to amyloid-β deposits at all.

Alzheimer's disease is the single leading cause of dementia, which affects up to 50 million people around the world and is a leading cause of death in Australia. The paper is important because it provides a balanced counterpoint to a significant field of research that could affect how we think about the causes and treatments.

"The understanding of Alzheimer's disease causation is incomplete. In this article we have tracked how the modern-day perception of Alzheimer's emerged, we have highlighted where knowledge is lacking and we have suggested new directions for Alzheimer's research to take," says co-author Dr. Gary Morris, a postdoctoral scientist at UTS.

"The most important take-home message is that the understanding of normal brain function and dysfunction has grown enormously in the last few decades. We propose the hypothetical models for Alzheimer's disease causation need to evolve to accommodate these advances. In doing so, new therapeutic strategies will likely emerge."

At its core, Vissel and his team are advocating for what they see as the logical next step in the global fight against Alzheimer's. Their own research is focusing on a range of risk factors and how they combine to cause the disease.

"What's clear is that there are a lot of failing , there's desperation around the world to find solutions, so we really have to start thinking in a different way and this paper presents some suggestions for how to do that," says Vissel.

"In this paper, we provide important suggestions for how to go forward to conquer this disease.

"We are confident world efforts will get to a solution."

Explore further: Alzheimer's disease – don't give up on plaque-busting drugs just yet

More information: Gary P. Morris et al. Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease, Acta Neuropathologica (2018). DOI: 10.1007/s00401-018-1918-8

Related Stories

Alzheimer's disease – don't give up on plaque-busting drugs just yet

September 28, 2018
Alzheimer's disease is associated with a build-up of plaques in the brain called amyloid beta. These plaques are thought to lead to a loss of neurons, which then causes the classic symptoms of the disease – including memory ...

Scientists discover why some people with brain markers of Alzheimer's have no dementia

August 16, 2018
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the ...

Can aspirin treat Alzheimer's?

July 2, 2018
A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological researchers at Rush University Medical Center, who published ...

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Daytime sleepiness linked to Alzheimer's

April 17, 2018
Do you catch yourself yawning during the day and yearning for an afternoon nap? You could be at more risk for Alzheimer's disease. A recent study published in JAMA Neurology found a potential link between excessive daytime ...

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Recommended for you

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.

Diabetes medications may reduce Alzheimer's disease severity

November 1, 2018
People with Alzheimer's disease who were treated with diabetes drugs showed considerably fewer markers of the disease—including abnormal microvasculature and disregulated gene expressions—in their brains compared to Alzheimer's ...

Massive study confirms that loneliness increases risk of dementia

October 29, 2018
A new Florida State University College of Medicine study involving data from 12,000 participants collected over 10 years confirms the heavy toll that loneliness can take on your health: It increases your risk of dementia ...

Bioactive compound from the Rhodiola plant improves memory

October 25, 2018
In an ageing society, more people are suffering from memory disorders. The progressive loss of memory severely impairs the quality of life of those affected. So far, no drugs are known to prevent age-related cognitive decline.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.